CHELI, STEFANIA
CHELI, STEFANIA
Universita' degli Studi di MILANO
ABCC4 single-nucleotide polymorphisms as markers of tenofovir disoproxil fumarate-induced kidney impairment
2021 S. Cheli, S. Baldelli, A. De Silvestri, M. Fusi, D. Minisci, C. Gervasoni, D. Cattaneo, E. Clementi, P. Meraviglia, C. Montrasio
ACE inhibitors and ribavirin-associated cough: a common undefined predisposing factor?
2013 L. Milazzo, D. Cattaneo, S. Cheli, L. Ferraris, E. Colella, E.G.I. Clementi, C. Gervasoni
Autophagy as a new therapeutic target in Duchenne muscular dystrophy
2012 C. De Palma, F. Morisi, S. Cheli, S. Pambianco, V. Cappello, M. Vezzoli, P. Rovere Querini, M. Moggio, M. Ripolone, M. Francolini, M. Sandri, E. Clementi
Clinical and genetic determinants of nevirapine plasma trough concentration
2018 A. Giacomelli, S. Rusconi, F.S. Falvella, M.L. Oreni, D. Cattaneo, V. Cozzi, G. Renisi, E. Monge, S. Cheli, E. Clementi, A. Riva, M. Galli, A.L. Ridolfo
Different effects of glucocorticoids on darunavir plasma concentrations
2019 D. Cattaneo, S. Cheli, M. Fusi, E. Clementi, C. Gervasoni
DIFFERENTIATING MUSCLE REQUIRES EARLY COORDINATED CHANGES IN MITOCHONDRIAL DYNAMICS : NITRIC OXIDE AS TASKMASTER OF DRP-1 ACTIVITY AND LOCALIZATION
2007 S. Falcone, C. De Palma, S. Pisoni, S. Cheli, S. Brunelli, L. Scorrano, E. Clementi
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecan
2015 F.S. Falvella, S. Cheli, A. Martinetti, C. Mazzali, R. Iacovelli, C. Maggi, M. Gariboldi, M.A. Pierotti, M. Di Bartolomeo, E. Sottotetti, R. Mennitto, I. Bossi, F. de Braud, E. Clementi, F. Pietrantonio
HLA-B*57: 01 testing : Care in interpreting the quality of different genotyping methods
2017 F.S. Falvella, S. Cheli, E. Clementi
In linezolid underexposure, pharmacogenetics matters: The role of CYP3A5
2021 S. Cheli, M. Fusi, A. De Silvestri, I. Bonini, E. Clementi, D. Cattaneo, C. Montrasio, S. Baldelli
Intra-chromosomal looping within FSHD locus provides the epigenitic link between D4Z4 array and FRG1 gene expression
2008 B. Bodega, G.A. DI CAPUA, S. Cheli, F. Grasser, S. Mueller, A. Marozzi, E. Battaglioli, E. Ginelli
Is a pharmacogenomic panel useful to estimate the risk of oxaliplatin-related neurotoxicity in colorectal cancer patients?
2019 F. Nichetti, F.S. Falvella, R. Miceli, S. Cheli, R. Gaetano, G. Fucà, G. Infante, A. Martinetti, C. Antoniotti, A. Falcone, M. Di Bartolomeo, C. Cremolini, F. de Braud, F. Pietrantonio
ITPA and SLC29A1 Genotyping for the Prediction of Ribavirin Dose Reduction in Anti-HCV Triple Therapy with Protease Inhibitors
2015 A. Lombardi, S. Landonio, C. Magni, S. Cheli, C. Mazzali, M.U. Mondelli, G. Rizzardini, E. Clementi, F.S. Falvella
Levofloxacin-induced seizures in a patient without predisposing risk factors : the impact of pharmacogenetics
2013 C. Gervasoni, D. Cattaneo, F.S. Falvella, P. Vitiello, S. Cheli, L. Milazzo, E. Clementi, A. Riva
LightSNiP assay is a good strategy for pharmacogenetics test
2015 S. Cheli, F. Pietrantonio, E. Clementi, F.S. Falvella
LINEE CELLULARI DERIVATE DA PAZIENTI AFFETTI DA DISTROFIA FACIO-SCAPOLO-OMERALE (FSHD) DI TIPO 1 E 2 MOSTRANO LUNGO IL DIFFERENZIAMENTO MIOGENICO PROFILI DIVERSI DI ESPRESSIONE GENICA.
2010 S. Cheli
Neonatal Outcomes in Maternal Depression in Relation to Intrauterine Drug Exposure
2019 S. Corti, P. Pileri, M.I. Mazzocco, C. Mando', A.F. Moscatiello, D. Cattaneo, S. Cheli, S. Baldelli, P. Laura, E.G.I. Clementi, I. Cetin
Pharmacogenetic approach to losartan in Marfan patients : A starting point to improve dosing regimen?
2016 F.S. Falvella, S. Marelli, S. Cheli, S. Montanelli, F. Viecca, L. Salvi, A. Ferrara, E. Clementi, G. Trifirò, A. Pini
Remodeling of the chromatin structure of the facioscapulohumeral muscular dystrophy (FSHD) locus and upregulation of FSHD-related gene 1 (FRG1) expression during human myogenic differentiation
2009 B. Bodega, G. Di Capua, F. Grasser, S. Cheli, S. Brunelli, M. Mora, R. Meneveri, A. Marozzi, S. Mueller, E. Battaglioli, E. Ginelli
Renal function in HIV/HBV co-infected and HBV mono-infected patients on a long-term treatment with tenofovir in real life setting
2017 L. Milazzo, C. Gervasoni, F.S. Falvella, D. Cattaneo, C. Mazzali, P. Ronzi, F. Binda, S. Cheli, S. Sollima, S. Antinori
Single nucleotide polymorphisms to predict taxanes toxicities and effectiveness in cancer patients
2021 S. Demurtas, N. La Verde, S. Rota, G. Casazza, C. Montrasio, S. Cheli, M.S. Cona, D. Dalu, C. Fasola, S. Ferrario, V. Filipazzi, A. Gambaro, N. Tosca, E. Clementi